



COS-LEP Phase 4 Delphi Survey Round 2

Breakdown Analysis



Criteria for Consensus to proceed by domain

- Any outcome rated 7–9 on Likert scale (critical outcome) by $\geq 70\%$ of any participant and 1–3 (limited importance) by no more than 15% of any single stakeholder group.
- Outcomes meeting this criteria advance.
- N=58 outcome types met this criteria**

Criteria for No consensus by domain

- Any outcome type **not meeting** the Consensus In **or** Out criteria will be defined as No consensus.
- These outcomes will not proceed to consensus meeting unless agreed by the COS-LEP steering committee.
- N=133 outcome types met this criteria**

Criteria for Consensus Out

Any outcome with $\geq 70\%$ of all participants rated 1–3 (not important) for an outcome in any round. Outcomes fulfilling this criteria will not proceed.

No outcomes met this criteria

Legend

* outcome did not meet criteria for consensus in Round 1

^ new outcome generated during Round 1

COMET Core Area – Mortality (Summary)

Summary of Core Area

• Outcome advancing

- All-cause Mortality, Mortality attributable to Leptospirosis, Survival at a future defined time point

• Outcomes not advancing

- *Time to death

COMET Core Area – Physiological/Clinical

Summary of Core Area

Outcome advancing

- **Blood and Lymphatic systems** – disseminated intravascular coagulation (DIC), *revealed bleed, *platelet count, *thrombocytopenia
- **Cardiac** - ^myositis
- **General outcomes** – haemodynamic shock, multi-organ failure, *morbidity (non-specific)
- **Hepatobiliary** – liver failure, *clinical jaundice, *hyperbilirubinaemia
- **Immune system** - *Change in immune/inflammatory biochemical markers
- **Infection and Infestation** – *Manifestation of severe disease
- **Nervous system** – Improving CNS manifestations, CNS haemorrhagic manifestations
- **Pregnancy, puerperium, and perinatal** – fetal death, neonatal death, preterm birth, adverse infant/fetal outcomes (general), admission to neonatal intensive care, *low birth weight, *live birth, *term birth, *median gestational age at delivery
- **Renal and urinary** – acute kidney injury, oliguria, biochemical measurements of renal function (general), normalisation of renal function, major adverse kidney event (death, need for renal replacement, and persistent renal dysfunction)
- **Respiratory, thoracic, and mediastinal** – Respiratory distress, severity of respiratory distress, respiratory failure, respiratory complications

Summary of Core Area (cont)

Outcomes not advancing

- **Blood and Lymphatic systems** – *Presence of anaemia, *duration of anaemia, *change in haemoglobin levels, *duration of bleed, *leukocytosis, *erythrocyte sedimentation rate (ESR) level, *haematocrit, *normalisation of haematological parameters (non-specific), *improvement of platelet counts (non-specific), days until normalisation of platelets
- **Cardiac** – *cardiac manifestations (non-specific), *ECG abnormalities, *cardiac arrhythmia, *normalisation of cardio-respiratory function (non-specific), ^pericarditis
- **Ear** - hearing
- **Eye** – ^uveitis, *prevention of conjunctival suffusion, *duration of conjunctival suffusion
- **Gastrointestinal** – *pancreatitis (general), *pancreatitis (by subtype), *complications of pancreatitis, *bedside index for severity in acute pancreatitis, *duration of gastrointestinal symptoms (non-specific), *gastrointestinal haemorrhage
- **General outcomes** – Duration of malaise, *collapse, *duration of vomiting, *duration of myalgia, *duration of general symptoms, *development of any complications at set timepoint, *change in clinical characteristics, *change in functional signs, *inadequate clinical response, *time to resolution of organ dysfunction, *resolution of symptoms (non-specific), *time to resolution of symptoms (non-specific), *resolution of symptoms at set time period
- **Hepatobiliary** – *hepatic tenderness, *change in bilirubin values, *normalisation of liver function (non-specific), *need for cholecystectomy
- **Immune system** – ^procalcitonin, ^C-reactive protein, *improvement of parameters of oxidative stress and increase in antioxidant capacity, *association of inflammatory marker with onset of Jarisch-Herxheimer reaction
- **Infection and Infestation** – prevention of confirmed case of leptospirosis, complication of leptospirosis (general), prevention of clinical manifestation of disease, prevention of clinical manifestation of disease confirmed by laboratory testing, *days of fever, *resolution of fever within specified time frame, *persistent fever, *prevention of the clinical diagnosis of leptospirosis, *prevention of probable case of leptospirosis, *prevention of seroconversion indicative of disease, *baseline IgM remains zero, *baseline IgM non-zero, *presence of antibodies to leptospira species, *fourfold rise in antibody titre, *rising antibody titre, *decreasing antibody titre, *revert to negative microscopic agglutination test, *change in leptospira antibody levels over time, *positive blood culture, *positive urine culture, *growth inhibition testing on serum, *no evolution in infection, *stable disease, *attack rates, *quantitative change in leptospiraemia, *persistent immune response to subsequent infection, chronic post-leptospirosis symptoms
- **Musculoskeletal and connective tissue** – ^Myalgia, ^muscle weakness, *symptoms of arthritis
- **Nervous system** – encephalopathy, seizure, *meningitis syndrome, *disease associated paralysis, *duration of headache
- **Pregnancy, puerperium, and perinatal** – *median neonatal birth weight

- **Renal and urinary** – renal failure, change in urine output, development of chronic kidney disease (CKD), stage of CKD (various criteria), *intradialysis mean arterial pressure (mmHg), *time to recovery of renal function, *fluid balance, *fluid intake (net/gross)
- **Respiratory, thoracic and mediastinal** – Development of pulmonary haemorrhage, *partial pressure of arterial blood oxygen by the fraction of inspired oxygen (P/F) ratio, *evolution of lung pathology, *normalisation of cardio-respiratory functions, *normalisation of radiographic imaging

COMET Core Area – Life Impact

Summary of Core Area

Outcome advancing

- **Delivery of care** – reduce outbreak events, health system responsiveness/readiness for outbreaks, accessibility to healthcare, *development of antimicrobial resistance
- **Role Functioning** - ^Impact of disease on ability to perform occupation

Outcomes not advancing

- **Global quality of life** – quality of life (non-specific)
- **Cognitive functioning** – ^Change in general cognitive function, *knowledge/awareness of risk factors, *behaviour related to risk factors
- **Delivery of care** – Adherence to assigned intervention
- **Personal circumstances** – *days lost from work, *duration until return to normal work

COMET Core Area – Resource Use

Summary of Core Area

Outcome advancing

- **Economic** – cost-effectiveness of treatment
- **Hospital** –need for hospitalisation, days of hospitalisation, days of hospitalisation attributable to leptospirosis, intensive treatment unit admission, duration of intensive treatment unit admission, need for hospitalisation attributable to leptospirosis, complete medical discharge from hospital/clinic
- **Need for further intervention** – need for high-flow nasal oxygen, need for extracorporeal membrane oxygenation, need for inotropic support, need for dialysis, renal replacement free survival, need for haemofiltration, major adverse kidney event, treatment failure

Outcomes not advancing

- **Economic** – *economic outcomes, ^self-reported cost of burden of disease, ^cost burden related to travel for medical intervention
- **Hospital** - days of clinical illness, ^need for inpatient physical rehabilitation, ^need for outpatient physical rehabilitation, ^need for hospital transfer
- **Need for further intervention** – duration of antibiotic use, need for subsequent antimicrobials, ^need for diuretics, ^need for immunosuppressive therapy, ^duration of immunosuppressive therapy, ^need for multi/single organ support, *need for mechanical ventilation, *duration of mechanical ventilation, *need for non-invasive ventilation, *duration of extracorporeal membrane oxygenation, *duration of inotropic support, *number of dialysis sessions, *duration of dialysis, *ultrafiltration rate (ml/dialysis session), *need for blood product transfusion, *partial treatment response

COMET Core Area – Adverse events

Summary of Core Area

Outcome advancing

- **Adverse events/effects** – drug safety, serious adverse events, safety (general)

Outcomes not advancing

- **Adverse events/effects** – *manifestations of Jarisch-Herxheimer reaction, *Jarisch-Herxheimer reaction manifestation association by antibiotic type, *manifestation of nosocomial infection, *non-serious adverse events, *adverse events/side effects (non-specific)

COMET Core Area – Mortality (Detailed breakdown)

Detailed analysis by outcome type

All-cause mortality

Overall 96% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Mortality attributable to Leptospirosis

Overall 96% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Survival at a future defined time point

Overall 82% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 0%
- Global health researcher group 12%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

*Time to death

Overall 69% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 6%
- Global health researcher group 12%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 0%

COMET Core Area – Physiological/Clinical

Detailed analysis by outcome domain and type

Blood and Lymphatic systems

DIC

Overall 86% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 31%
- Global health researcher group 18%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Overall 71% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 6%
- Global health researcher group 6%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

***Anaemia**

Overall 57% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 13%
- Global health researcher group 0%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

***Change in haemoglobin levels**

Overall 52% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 25%
- Global health researcher group 6%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

***Duration of bleed**

Overall 62% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 25%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

***Duration of Anaemia**

Overall 50% rated ≥ 7

***Revealed bleed**

***Leukocytosis**

Overall 61% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 13%
- Global health researcher group 12%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

***ESR**

Overall 49% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 16%
- Other specialty clinician group 31%
- Global health researcher group 6%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

***Platelet count**

Overall 71% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 6%

- Global health researcher group 12%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

***Thrombocytopenia**

Overall 72% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 13%
- Global health researcher group 6%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

***Haematocrit level**

Overall 58% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%
- Other specialty clinician group 31%
- Global health researcher group 6%
- Allied Health Profession group 0%

- Patient/General Public group 0%
- Policymaker group 100%

***Normalisation of haematological parameters (non-specific)**

Overall 52% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%
- Other specialty clinician group 25%
- Global health researcher group 6%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

***Improvement of platelet counts (non-specific)**

Overall 56% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 25%
- Global health researcher group 6%
- Allied Health Profession group 0%
- Patient/General Public group 0%

- Policymaker group 100%

***Days until normalisation of platelets**

Overall 49% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

Cardiac

***Non-specific cardiac manifestations**

Overall 61% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 6%
- Global health researcher group 6%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

***ECG abnormality**

Overall 50% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 19%
- Global health researcher group 0%
- Allied Health Profession group 25%

- ID clinician group 10%
- Other specialty clinician group 19%
- Global health researcher group 12%

- Patient/General Public group 0%

***Cardiac arrhythmia**

Overall 64% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 13%
- Global health researcher group 0%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 0%

***Normalisation of cardio-respiratory functions (non-specific)**

Overall 63% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 19%

- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

^Cardiac myositis

Overall 71% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

^Pericarditis

Overall 63% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0=6%
- Other specialty clinician group 19%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Eye

^Uveitis

Overall 61% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 13%
- Global health researcher group 12%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

- Global health researcher group 24%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 0%

***Duration of conjunctival suffusion**

Overall 46% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 19%
- Other specialty clinician group 31%
- Global health researcher group 24%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 0%

***Prevention of conjunctival suffusion**

Overall 42% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 16%
- Other specialty clinician group 25%

Ear

Hearing

Overall 49% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 6%
- Global health researcher group 24%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Gastrointestinal

***Pancreatitis (general)**

Overall 57% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%

- Other specialty clinician group 6%
- Global health researcher group 6%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

*Pancreatitis (by sub-type)

Overall 53% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 19%
- Global health researcher group 18%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

*Complications of pancreatitis

Overall 54% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 19%
- Global health researcher group 12%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

*Bedside for severity in acute pancreatitis

Overall 51% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 25%
- Global health researcher group 12%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

*Duration of gastrointestinal symptoms (non-specific)

Overall 43% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 16%
- Other specialty clinician group 31%
- Global health researcher group 29%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

*Gastrointestinal haemorrhage

Overall 60% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 19%
- Global health researcher group 6%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

General outcomes

Haemodynamic shock

Overall 86% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%

- Global health researcher group 0%

- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Multi-organ failure

Overall 94% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 10%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Duration of malaise

Overall 44% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 19%
- Other specialty clinician group 6%
- Global health researcher group 18%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

***Morbidity (non-specific)**

Overall 74% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 13%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

***Collapse**

Overall 53% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 25%
- Global health researcher group 12%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

***Duration of vomiting**

Overall 40% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 16%
- Other specialty clinician group 31%
- Global health researcher group 23%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

***Duration of myalgia**

Overall 38% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%
- Other specialty clinician group 19%
- Global health researcher group 29%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

***Duration of general symptoms**

Overall 49% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 19%

- Global health researcher group 18%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 0%

***Development of any complication at a set timepoint**

Overall 69% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 13%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

***Change in clinical characteristics**

Overall 65% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 19%
- Global health researcher group 6%

- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

***Change in functional signs**

Overall 61% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 19%
- Global health researcher group 6%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

***Inadequate clinical response**

Overall 65% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 13%
- Global health researcher group 12%
- Allied Health Profession group 0%
- Patient/General Public group 0%

- Policymaker group 0%

Time to resolution of organ dysfunction

Overall 71% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 13%
- Global health researcher group 6%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Resolution of symptoms (non-specific)

Overall 63% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 13%
- Global health researcher group 29%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 0%

Time to resolution of symptoms (non-specific)

Overall 57% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 19%
- Global health researcher group 29%
- Allied Health Profession group 0%

- Patient/General Public group 0%
- Policymaker group 100%

Resolution of symptoms at set time period

Overall 51% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%

- Other specialty clinician group 19%
- Global health researcher group 24%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Hepatobiliary

Liver failure

Overall 81% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

- Global health researcher group 12%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Clinical jaundice

Overall 76% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 6%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Hyperbilirubinaemia

Overall 78% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 6%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Hepatic tenderness

Overall 54% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 13%

Change in bilirubin levels

Overall 67% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 13%

- Global health researcher group 6%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Normalization of liver function (non-specific)

Overall 63% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%

- Other specialty clinician group 19%
- Global health researcher group 12%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Need for cholecystectomy

Overall 40% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 32%
- Other specialty clinician group 31%
- Global health researcher group 29%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Immune system

Procalcitonin

Overall 61% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 16%
- Other specialty clinician group 25%
- Global health researcher group 0%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Overall 71% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 13%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

C-reactive protein

Overall 58% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 16%
- Other specialty clinician group 19%
- Global health researcher group 6%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Improvement of parameters of oxidative stress and increase antioxidant capacity

Overall 53% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 16%
- Other specialty clinician group 19%
- Global health researcher group 18%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Immune/inflammatory biochemical markers

Association of inflammatory marker with onset of Jarisch–Herxheimer reaction

Overall 50% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%
- Other specialty clinician group 6%

- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 33%
- Policymaker group 100%

Infection and Infestation

Prevention of confirmed case of leptospirosis

Overall 78% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 0%
- Global health researcher group 6%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 0%

Prevention of clinical manifestation of disease

Overall 69% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 6%
- Global health researcher group 0%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

- Patient/General Public group 0%
- Policymaker group 0%

Chronic post-leptospirosis symptoms

Overall 61% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 13%
- Global health researcher group 12%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Complication of Leptospirosis (general)

Overall 83% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 6%
- Global health researcher group 0%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 0%

Prevention of clinical manifestation of disease confirmed by laboratory testing

Overall 74% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 6%
- Global health researcher group 0%
- Allied Health Profession group 25%

Days of fever

Overall 58% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 13%
- Global health researcher group 12%

- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 0%

Resolution of fever within specified time frame

Overall 49% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 19%
- Global health researcher group 24%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 0%

Persistent fever

Overall 67% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 19%
- Global health researcher group 18%
- Allied Health Profession group 0%
- Patient/General Public group 0%

- Policymaker group 100%

Prevention of the clinical diagnosis of leptospirosis

Overall 75% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 13%
- Global health researcher group 6%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Prevention of probable case of leptospirosis

Overall 61% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 13%
- Global health researcher group 6%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Prevention of seroconversion indicative of disease

Overall 50% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 25%
- Global health researcher group 18%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Baseline IgM remains zero

Overall 44% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 16%
- Other specialty clinician group 25%
- Global health researcher group 35%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Baseline IgM non-zero

Overall 46% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 16%
- Other specialty clinician group 25%
- Global health researcher group 35%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Presence of antibodies to *Leptospira* spp

Overall 63% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 13%
- Global health researcher group 18%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Fourfold rise in antibody titre

Overall 79% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 13%

- Global health researcher group 6%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Rising antibody titre

Overall 75% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 13%
- Global health researcher group 6%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Decreasing antibody titre

Overall 53% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 16%
- Other specialty clinician group 13%
- Global health researcher group 35%
- Allied Health Profession group 25%

- Patient/General Public group 0%
- Policymaker group 100%

Revert to negative MAT

Overall 54% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%
- Other specialty clinician group 19%
- Global health researcher group 18%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Change in *Leptospira* antibody levels over time

Overall 61% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 13%
- Global health researcher group 24%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Positive blood culture

Overall 63% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 16%
- Other specialty clinician group 6%
- Global health researcher group 24%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Positive urine culture

Overall 61% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 6%
- Global health researcher group 29%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Growth inhibition testing on serum

Overall 53% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 19%
- Other specialty clinician group 19%

- Global health researcher group 47%

- Allied Health Profession group 25%

- Patient/General Public group 0%

- Policymaker group 100%

No evolution in infection

Overall 47% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%

- Other specialty clinician group 38%

- Global health researcher group 29%

- Allied Health Profession group 25%

- Patient/General Public group 0%

- Policymaker group 100%

Stable disease

Overall 57% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%

- Other specialty clinician group 25%

- Global health researcher group 41%

- Allied Health Profession group 25%

- Patient/General Public group 0%

- Policymaker group 100%

Manifestation of severe disease

Overall 85% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%

- Other specialty clinician group 13%

- Global health researcher group 0%

- Allied Health Profession group 0%

- Patient/General Public group 0%

- Policymaker group 0%

Attack rates

Overall 58% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%

- Other specialty clinician group 38%

- Global health researcher group 18%

- Allied Health Profession group 25%

- Patient/General Public group 0%

- Policymaker group 100%

Quantitative change in leptospirosis

Overall 58% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 25%
- Global health researcher group 6%

- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Persistent immune response to subsequent infection

Overall 57% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 31%
- Global health researcher group 24%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Musculoskeletal and connective tissue

Myalgia

Overall 68% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 6%
- Global health researcher group 6%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

- Global health researcher group 6%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Symptoms of arthritis

Overall 39% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 16%
- Other specialty clinician group 25%
- Global health researcher group 29%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Muscle weakness

Overall 58% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%
- Other specialty clinician group 6%

Nervous system

Improving CNS manifestations

Overall 81% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 6%

- Global health researcher group 0%
- Allied Health Profession group 0%

- Patient/General Public group 0%
- Policymaker group 100%

Encephalopathy

Overall 79% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Seizure

Overall 74% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 6%
- Global health researcher group 0%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

CNS haemorrhagic manifestation

Overall 74% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 6%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Meningitis syndrome

Overall 78% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 19%
- Global health researcher group 0%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 0%

Disease associated paralysis

Overall 60% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 25%
- Global health researcher group 12%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Duration of headache

Overall 43% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%
- Other specialty clinician group 31%
- Global health researcher group 18%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Pregnancy, puerperium, and perinatal

Fetal death

Overall 90% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Neonatal death

Overall 89% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Preterm birth

Overall 86% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 6%

- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Adverse infant/fetal outcome (general)

Overall 86% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 10%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Admission to neonatal intensive care

Overall 83% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

- Policymaker group 0%

Low birth weight

Overall 76% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 6%
- Global health researcher group 6%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Live birth

Overall 76% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 6%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Term birth

Overall 74% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%

- Other specialty clinician group 6%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- **Policymaker group 100%**

Median neonatal birth weight

Overall 68% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- **Other specialty clinician group 19%**
- Global health researcher group 6%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- **Policymaker group 100%**

Median gestational age at delivery

Overall 74% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 13%
- Global health researcher group 6%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- **Policymaker group 100%**

Renal and urinary

Renal failure

Overall 89% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%
- **Allied Health Profession group 25%**
- Patient/General Public group 0%
- Policymaker group 0%

- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Change in urine output

Overall 69% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 0%
- Global health researcher group 6%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Oliguria

Overall 72% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 0%

Acute kidney injury

Overall 94% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%

- Policymaker group 0%

Biochemical measurements of renal function (general)

Overall 76% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Development of chronic kidney disease (CKD)

Overall 69% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 6%
- Global health researcher group 0%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Stage of CKD (various criteria)

Overall 67% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 19%
- Global health researcher group 0%
- Allied Health Profession group 14%
- Patient/General Public group 0%
- Policymaker group 100%

Normalisation of renal function

Overall 81% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Major Adverse Kidney Event

Overall 90% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 6%

- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Intradialysis mean arterial pressure (mmHg)

Overall 64% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 19%
- Global health researcher group 6%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Time to recovery of renal function

Overall 71% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 19%
- Global health researcher group 6%

- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Fluid balance

Overall 64% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 19%

- Global health researcher group 12%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Fluid intake (net/gross)

Overall 63% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%

- Other specialty clinician group 19%
- Global health researcher group 12%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Respiratory, thoracic and mediastinal

Development of pulmonary haemorrhage

Overall 88% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 0%

Respiratory distress

Overall 81% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%

- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Severity of respiratory distress

Overall 86% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%

- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Respiratory failure

Overall 86% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Respiratory complications

Overall 76% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Partial pressure of arterial blood oxygen by the fraction of inspired oxygen (P/F) ratio

Overall 76% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 19%
- Global health researcher group 0%
- Policymaker group 100%

- Allied Health Profession group 0%

- Patient/General Public group 0%

- Policymaker group 100%

Evolution of lung pathology

Overall 71% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%

- Other specialty clinician group 19%

- Global health researcher group 6%

- Allied Health Profession group 0%

- Patient/General Public group 0%

- Policymaker group 100%

Normalisation of cardio-respiratory functions

Overall 68% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%

- Other specialty clinician group 25%

- Global health researcher group 6%

- Allied Health Profession group 0%

- Patient/General Public group 0%

- Policymaker group 100%

Normalisation of radiographic imaging

Overall 56% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%

- Other specialty clinician group 25%

- Global health researcher group 12%

- Allied Health Profession group 25%

- Patient/General Public group 0%

COMET Core Area – Life Impact (Detailed breakdown)

Detailed analysis by outcome domain and type

Cognitive functioning

Change in general cognitive function

Overall 68% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 13%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Knowledge/awareness of risk factors

Overall 76% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 7%

- Other specialty clinician group 19%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Behaviour related to risk factors

Overall 76% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 19%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Global quality of life

Quality of life (non-specific)

Overall 66% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Delivery of care

Reduce outbreak events

Overall 81% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 0%

- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Health system responsiveness/readiness for outbreaks

Overall 84% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%

- Other specialty clinician group 6%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Accessibility to healthcare

Overall 85% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%

- Allied Health Profession group 0%
- Patient/General Public group 100%

Adherence to assigned intervention

Overall 82% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 5%
- Allied Health Profession group 25%
- Patient/General Public group 0%

- Policymaker group 100%

Development of antimicrobial resistance

Overall 71% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 13%
- Global health researcher group 12%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Personal circumstances

Days lost from work

Overall 67% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 13%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Days lost from work

Overall 68% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 13%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Role Functioning

Impact of disease on ability to perform occupation

Overall 71% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 6%

- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

COMET Core Area – Resource Use (Detailed breakdown)

Detailed analysis by outcome domain and type

Economic

Cost-effectiveness of treatment

Overall 74% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 6%
- Global health researcher group 12%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Cost burden related to travel for medical intervention

Overall 61% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 0%
- Global health researcher group 6%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Self-reported cost of burden of disease

Overall 63% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 6%
- Global health researcher group 6%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- **Policymaker group 100%**

Economic outcomes

Overall 67% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 13%
- Global health researcher group 6%
- **Allied Health Profession group 33%**
- Patient/General Public group 0%
- Policymaker group 0%

Hospital

Days of clinical illness

Overall 76% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%

- **Allied Health Profession group 25%**
- Patient/General Public group 0%
- Policymaker group 0%

Need for hospitalisation

Overall 79% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

- Policymaker group 0%

Days of hospitalisation

Overall 75% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Days of hospitalisation attributable to leptospirosis

Overall 74% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Intensive Treatment Unit admission

Overall 81% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Duration of Intensive Treatment Unit admission

Overall 85% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Need for hospitalisation attributable to leptospirosis

Overall 79% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%

- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Complete medical discharge from hospital/clinic

Overall 71% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 6%
- Global health researcher group 6%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Need for inpatient physical rehabilitation

Overall 57% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 13%
- Global health researcher group 18%

- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Need for outpatient physical rehabilitation

Overall 49% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%
- Other specialty clinician group 13%

- Global health researcher group 18%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Need for hospital transfer

Overall 71% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%

- Other specialty clinician group 19%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Need for further intervention

Duration of antibiotic case

Overall 71% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 13%
- Global health researcher group 0%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 0%

- ID clinician group 6%
- Other specialty clinician group 6%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Need for extracorporeal membrane oxygenation

Overall 72% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 0%

Need for inotropic support

Overall 82% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%

Need for high-flow nasal oxygen

Overall 74% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- Patient/General Public group 0%
- Policymaker group 0%

Need for dialysis

Overall 89% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Renal replacement free survival

Overall 78% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Need for haemofiltration

Overall 78% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Major adverse kidney event

Overall 90% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Treatment failure

Overall 79% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 0%

- Global health researcher group 12%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Need for subsequent antimicrobial

Overall 64% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%
- Other specialty clinician group 0%
- Global health researcher group 12%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Need for diuretic

Overall 57% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 25%

- Patient/General Public group 0%
- Policymaker group 100%

Need for immunosuppressive therapy

Overall 69% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 13%
- Global health researcher group 12%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Duration of immunosuppressive therapy

Overall 61% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 13%
- Global health researcher group 6%
- Allied Health Profession group 25%
- Patient/General Public group 0%

- Policymaker group 100%

Need for multi/single organ support

Overall 71% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Need for mechanical ventilation

Overall 81% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Duration of mechanical ventilation

Overall 78% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 19%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 100%

Need for non-invasive ventilation

Overall 81% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Duration of extracorporeal membrane oxygenation

Overall 69% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%

- Other specialty clinician group 19%
- Global health researcher group 0%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Duration of inotropic support

Overall 72% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 19%
- Global health researcher group 0%
- Allied Health Profession group 50%
- Patient/General Public group 0%
- Policymaker group 100%

Number of dialysis sessions

Overall 69% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 19%

- Global health researcher group 5%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Duration of dialysis

Overall 69% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 31%
- Global health researcher group 5%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Ultrafiltration rate (ml/dialysis session)

Overall 64% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 19%
- Other specialty clinician group 31%
- Global health researcher group 6%
- Allied Health Profession group 25%

- Patient/General Public group 0%
- Policymaker group 100%

Need for blood product transfusion

Overall 72% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 13%
- Global health researcher group 0%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

Partial treatment response

Overall 61% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 19%
- Global health researcher group 12%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 100%

COMET Core Area – Adverse events (Detailed breakdown)

Detailed analysis by outcome domain and type

Adverse events/effects

Drug safety

Overall 78% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 6%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Overall 76% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 6%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Jarisch-Herxheimer reaction manifestation association by antibiotic type

Overall 61% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 13%
- Global health researcher group 18%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 0%

Serious adverse events

Overall 86% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 6%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%

Manifestations of Jarisch-Herxheimer reaction

Overall 58% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 13%
- Global health researcher group 12%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 0%

Manifestation of nosocomial infection

Overall 71% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 3%
- Other specialty clinician group 13%
- Global health researcher group 6%
- Allied Health Profession group 25%

Safety (general)

- Patient/General Public group 0%
- Policymaker group 100%

Non-serious adverse events

Overall 46% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 25%

- Global health researcher group 6%
- Allied Health Profession group 25%
- Patient/General Public group 0%
- Policymaker group 0%

Adverse events/side effects (non-specific)

Overall 57% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 19%
- Global health researcher group 12%
- Allied Health Profession group 0%
- Patient/General Public group 0%
- Policymaker group 0%